CN113891719A - 包含电荷修饰的珠蛋白的抗肿瘤的细胞 - Google Patents

包含电荷修饰的珠蛋白的抗肿瘤的细胞 Download PDF

Info

Publication number
CN113891719A
CN113891719A CN202080034502.XA CN202080034502A CN113891719A CN 113891719 A CN113891719 A CN 113891719A CN 202080034502 A CN202080034502 A CN 202080034502A CN 113891719 A CN113891719 A CN 113891719A
Authority
CN
China
Prior art keywords
lys
cell
gly
leu
globin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080034502.XA
Other languages
English (en)
Chinese (zh)
Inventor
亚当·威廉斯·佩里曼
本杰明·迈克尔·卡特
托马斯·莱恩·菲利普·格林
大卫·科埃
W·H·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New Cell Therapy Ltd
Original Assignee
New Cell Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Cell Therapy Ltd filed Critical New Cell Therapy Ltd
Publication of CN113891719A publication Critical patent/CN113891719A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080034502.XA 2019-03-06 2020-03-06 包含电荷修饰的珠蛋白的抗肿瘤的细胞 Pending CN113891719A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1902992.5A GB201902992D0 (en) 2019-03-06 2019-03-06 Product and method
GB1902992.5 2019-03-06
PCT/GB2020/050537 WO2020178598A1 (en) 2019-03-06 2020-03-06 Antitumor cell comprising a charge modified globin

Publications (1)

Publication Number Publication Date
CN113891719A true CN113891719A (zh) 2022-01-04

Family

ID=66377289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034502.XA Pending CN113891719A (zh) 2019-03-06 2020-03-06 包含电荷修饰的珠蛋白的抗肿瘤的细胞

Country Status (9)

Country Link
US (1) US20220127317A1 (enExample)
EP (1) EP3934667A1 (enExample)
JP (1) JP2022524753A (enExample)
KR (1) KR20210135567A (enExample)
CN (1) CN113891719A (enExample)
AU (1) AU2020231078A1 (enExample)
CA (1) CA3131161A1 (enExample)
GB (1) GB201902992D0 (enExample)
WO (1) WO2020178598A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260234195A1 (en) * 2021-11-05 2026-08-13 University Of Kansas Active immunization against amyloid and aging-related diseases
GB202200962D0 (en) 2022-01-25 2022-03-09 Cytoseek Ltd Polymer additives
WO2025137409A1 (en) * 2023-12-21 2025-06-26 University Of Florida Research Foundation, Incorporated Supercharged lipid nanodiscs and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160272707A1 (en) * 2013-09-11 2016-09-22 Compugen Ltd. Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases
CN106137967A (zh) * 2015-04-24 2016-11-23 北京大学 靶向脑胶质瘤的双重修饰脂质体给药系统的制备和应用
WO2017222398A1 (en) * 2016-06-22 2017-12-28 Cellis Sp. Z O.O. Cellular targeted pharmaceutically active substance or label delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297182A4 (en) 2008-04-28 2012-08-15 Harvard College HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION
JP2010215517A (ja) * 2009-03-13 2010-09-30 Terumo Corp 酸素親和性を中酸素親和性に制御したヘモグロビン含有リポソーム懸濁液
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
CA2849448C (en) * 2011-09-06 2020-03-24 Billion King International Limited Oral delivery for hemoglobin based oxygen carriers
FR3002146B1 (fr) 2013-02-15 2016-03-04 Hemarina Utilisation d'hemoglobine d'annelides pour traiter les cancers
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
EP3212221B1 (en) 2014-10-29 2023-12-06 Massachusetts Eye & Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160272707A1 (en) * 2013-09-11 2016-09-22 Compugen Ltd. Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases
CN106137967A (zh) * 2015-04-24 2016-11-23 北京大学 靶向脑胶质瘤的双重修饰脂质体给药系统的制备和应用
WO2017222398A1 (en) * 2016-06-22 2017-12-28 Cellis Sp. Z O.O. Cellular targeted pharmaceutically active substance or label delivery system

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAMES P.K. ARMSTRONG等: "Artificial membrane-binding proteins stimulate oxygenation of stem cells during engineering of large cartilage tissue", NATURE COMMUNICATIONS, vol. 6, no. 1, pages 2, XP055521280, DOI: 10.1038/ncomms8405 *
MADELINE BURKE等: "Regulation of Scaffold Cell Adhesion Using Artificial Membrane Binding Proteins", MACROMOLECULAR BIOSCIENCE, pages 1 - 9 *
MARIA GALLUZZO等: "Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 119, no. 4, pages 866 *
唐君: "新型多糖纳米囊包裹牛血红蛋白氧载体的构建", 中国优秀硕士学位论文全文数据库(电子期刊)医药卫生科技辑, pages 080 - 31 *

Also Published As

Publication number Publication date
US20220127317A1 (en) 2022-04-28
KR20210135567A (ko) 2021-11-15
GB201902992D0 (en) 2019-04-17
EP3934667A1 (en) 2022-01-12
JP2022524753A (ja) 2022-05-10
CA3131161A1 (en) 2020-09-10
AU2020231078A1 (en) 2021-10-21
WO2020178598A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
JP7758384B2 (ja) 抗原提示細胞模倣足場およびそれを作製および使用するための方法
AU2017234192B2 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
AU2018273958B2 (en) PD-1 and CTLA-4 dual inhibitor peptides
JP2020015760A (ja) キメラ抗原受容体t細胞スイッチおよびその使用
US20240050570A1 (en) T Cell Modification
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
CN111867618A (zh) T细胞制备组合物和方法
Hu et al. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy
CN106619515A (zh) 脂质体组合物及其用途
CN112048002A (zh) 一种靶向t细胞的酶敏感纳米体系及其制备方法和应用
CN111068069A (zh) 一种免疫靶向功能性脂质体及其制备方法与用途
JP2022524753A (ja) 電荷修飾グロビンを含む抗腫瘍細胞
JP2002541875A (ja) モデル膜システム
Janes et al. Dendritic cell immune modulation via polyphenol membrane coatings
EP4004034A1 (en) Mhc class ii molecules and methods of use thereof
JP2024521439A (ja) T細胞を活性化する方法
Zhang Engineering cellular immunotherapies using lipid-tailed antigen and adjuvant delivery
Yan Lipid nanoparticles mediated mRNA delivery for cancer immunotherapies
Xie Engineering T Cell Trafficking and Function for Enhanced Cancer Immunotherapy
WO2025206249A1 (ja) 膜係留型il-2、及びその利用
HK40084267A (en) Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
HK40084235A (en) Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
HK40083136A (en) Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
Halldórsdóttir Fantastic T cells and how to track them: Methods for tracking adoptively transferred T cells and enhancing efficacy of cellular therapies
CN120789242A (zh) 一种egfr l858r突变特异性长肽疫苗及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220104